Article
Oncology
Chunyang Mu, Junyi Shen, Xinrui Zhu, Wei Peng, Xiaoyun Zhang, Tianfu Wen
Summary: This study retrospectively analyzed the clinical data of 16 patients with unresectable recurrent hepatocellular carcinoma who received lenvatinib + TACE + PD-1 antibody conversion therapy. The results showed that this combination treatment is safe and effective, with a positive impact on patients' overall survival and progression-free survival rates.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jiashuo Chao, Shanshan Wang, Hao Wang, Nan Zhang, Yunchao Wang, Xu Yang, Chengpei Zhu, Cong Ning, Xinmu Zhang, Jingnan Xue, Longhao Zhang, Mingjian Piao, Mingming Wang, Xiaobo Yang, Ling Lu, Haitao Zhao
Summary: This retrospective cohort study evaluated the effectiveness and safety of PD-1 blockade plus lenvatinib in patients with advanced ICC. The study found that PD-L1 expression and CA19-9 level may predict treatment efficacy, while IDH1 mutations may indicate a better treatment response.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Jie Mei, Yu-Hao Tang, Wei Wei, Ming Shi, Lie Zheng, Shao-Hua Li, Rong-Ping Guo
Summary: The study found that compared to PL, HPL was associated with significantly better treatment response and survival benefits for patients with advanced HCC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Keisuke Enomoto, Shun Hirayama, Naoko Kumashiro, Xuefeng Jing, Takahito Kimura, Shunji Tamagawa, Ibu Matsuzaki, Shin-Ichi Murata, Muneki Hotomi
Summary: The study suggests that combining lenvatinib with MEK inhibitors may have potential therapeutic efficacy for treating radioiodine-refractory thyroid cancer, as demonstrated by in vitro and in vivo experiments validating the anti-tumor effects of this combination.
Review
Medicine, General & Internal
Ying Cheng, Hui Li, Liang Zhang, Jing-Jing Liu, Chang-Liang Yang, Shuang Zhang
Summary: In recent years, immune checkpoint inhibitors have made significant breakthroughs in the treatment of lung cancer, with combination immunotherapy being widely used to improve efficacy. The combination of PD-1/PD-L1 inhibitors with other treatment modalities is a current research focus.
CHINESE MEDICAL JOURNAL
(2021)
Review
Immunology
Bahman Abedi Kiasari, Arash Abbasi, Nadia Ghasemi Darestani, Nasim Adabi, Arsalan Moradian, Yalda Yazdani, Golsa Sadat Hosseini, Nasrin Gholami, Sheida Janati
Summary: Immune checkpoint inhibitor nivolumab has greatly improved the treatment outcomes for advanced cancer patients. However, monotherapy with nivolumab is not effective in a large proportion of patients. The rational combination of nivolumab with conventional and targeted therapies has been shown to enhance its efficacy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Endocrinology & Metabolism
Dongmei Huang, Jinming Zhang, Xiangqian Zheng, Ming Gao
Summary: Lenvatinib has shown meaningful antitumor activity but limited clinical efficacy in the treatment of anaplastic thyroid carcinoma (ATC).
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Paul Koller, Natalia Baran, Karine Harutyunyan, Antonio Cavazos, Saradhi Mallampati, Renee L. Chin, Zhou Jiang, Xian Sun, Heng-Huan Lee, Jennifer L. Hsu, Patrick Williams, Xuelin Huang, Michael A. Curran, Mien-Chie Hung, Marina Konopleva
Summary: This study found that the combination treatment with the tyrosine kinase inhibitor dasatinib and an anti-PD-1 antibody is highly effective in a preclinical model of Philadelphia chromosome positive B-cell acute lymphoblastic leukemia. The treatment decreases tumor burden, improves efficacy, and prolongs survival. Mechanistically, it increases MHC II expression on antigen-presenting cells and promotes influx of these cells into the leukemic bone marrow. The induction of MHC II may also enhance immune memory and impair leukemic engraftment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Endocrinology & Metabolism
Christine Dierks, Jochen Seufert, Konrad Aumann, Juri Ruf, Claudius Klein, Selina Kiefer, Michael Rassner, Melanie Boerries, Andreas Zielke, Paul la Rosee, Philipp Tobias Meyer, Matthias Kroiss, Christian Weissenberger, Tilmann Schumacher, Patrick Metzger, Harald Weiss, Constantin Smaxwil, Katharina Laubner, Justus Duyster, Nikolas von Bubnoff, Cornelius Miething, Oliver Thomusch
Summary: The combination therapy of lenvatinib and pembrolizumab may be safe and effective in patients with ATC/PDTC, resulting in complete and long-term remissions.
Article
Biochemistry & Molecular Biology
Kensuke Suzuki, Hiroshi Iwai, Keita Utsunomiya, Yumiko Kono, Tadashi Watabe, Yoshiki Kobayashi, Dan Van Bui, Shunsuke Sawada, Yasutaka Yun, Akitoshi Mitani, Kenta Fukui, Haruka Sakai, Hanh Hong Chu, Nguyen Manh Linh, Noboru Tanigawa, Akira Kanda
Summary: This study investigated the antitumor effects of combination therapy with lenvatinib and I-131 in differentiated thyroid cancer (DTC) cells with different sodium iodide symporter (NIS) status. The results demonstrated that lenvatinib treatment increased radioiodine uptake in NIS-expressing cells, but decreased uptake in non-expressing cells. The combination therapy synergistically inhibited colony formation and cell migration, especially in NIS-expressing cells. Furthermore, the treatment effectively inhibited tumor growth in a NIS-expressing thyroid cancer xenograft model. These findings suggest that lenvatinib should be administered after I-131 treatment for optimal efficacy in DTC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Yan-Yu Wang, Xu Yang, Yun-Chao Wang, Jun-Yu Long, Hui-Shan Sun, Yi-Ran Li, Zi-Yu Xun, Nan Zhang, Jing-Nan Xue, Cong Ning, Jun-Wei Zhang, Cheng-Pei Zhu, Long-Hao Zhang, Xiao-Bo Yang, Hai-Tao Zhao
Summary: This study evaluated the clinical outcome of PD-1 inhibitors combined with targeted drugs and locoregional therapy in patients with unresectable hepatocellular carcinoma. The results showed that patients who received the combination therapy had longer overall survival and progression-free survival, as well as better disease control rates. The safety profile of the treatment regimens was similar.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Wei-Jun Wang, Zong-Han Liu, Kang Wang, Hong-Ming Yu, Yu-Qiang Cheng, Yan-Jun Xiang, Jin-Kai Feng, Li-Ping Zhou, Hong-Kun Zhou, Wei-Wei Pan, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng
Summary: This retrospective study compared the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 inhibitors (T-L-P) versus TACE combined with lenvatinib (T-L) or TACE alone for unresectable recurrent hepatocellular carcinoma (HCC). The results showed that the T-L-P regimen was safe and superior to T-L or TACE alone in improving the survival of patients with unresectable recurrent HCC.
Article
Chemistry, Multidisciplinary
Fu Li, Jingrong Li, Ke Yin, Juan Zhang, Zhen-hu Li, Liang Lu, Yuan-wu Bao, Zhen Qin, Yong Zheng, Bao-tian Yang, Jing Li, Xinzhong Wang
Summary: The PD-1 antibody CS1003 is a novel humanized IgG4 PD-1 monoclonal antibody that can effectively inhibit immune regulation, promote T cell activity, and exhibit anti-tumor activity. Preclinical studies have shown the potential clinical application value of CS1003 in cancer immunotherapy.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Oncology
Adriana Hepner, Victoria G. Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne N. Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gerard, Olivier Michielin, Georgina V. Long, Alexander M. Menzies
Summary: This study retrospectively analyzed the efficacy and safety of ipilimumab re-induction in patients with advanced melanoma who developed acquired resistance after combination immunotherapy. The response rate to reinduction therapy was 26%, with a disease control rate of 45%. Clinicians should be cautious of immune-related adverse events, including the recurrence of events observed during induction therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang
Summary: This study retrospectively analyzed the efficacy and safety of anti-PD-1 antibody combined with lenvatinib therapy and chemotherapy as first-line treatment for unresectable stage IV gallbladder cancer. The results showed that the combined therapy group had a longer overall survival and progression-free survival compared to the chemotherapy group. The objective response rate was higher in the combined therapy group, although the difference was not significant. The combined therapy group also had fewer adverse events, demonstrating the advantage of this treatment approach.
Article
Gastroenterology & Hepatology
Doo-Ho Lee, Woongchang Yoon, Areum Lee, Youngmin Han, Yoonhyeong Byun, Jae Seung Kang, Hongbeom Kim, Wooil Kwon, Young-Ah Suh, Yonghwan Choi, Junghyun Namkung, Sangjo Han, Sung Gon Yi, Jin Seok Heo, In Woong Han, Joon Oh Park, Joo Kyung Park, Song Cheol Kim, Eunsung Jun, Chang Moo Kang, Woo Jin Lee, Hyeon Kook Lee, Huisong Lee, Seungyeoun Lee, Seung-Yong Jeong, Kyu Eun Lee, Wonshik Han, Taesung Park, Jin-Young Jang
Summary: This study developed a prediction model using a multi-marker panel as a diagnostic screening tool for pancreatic ductal adenocarcinoma and demonstrated its significant diagnostic performance in distinguishing pancreatic ductal adenocarcinoma from normal and benign pancreatic disease states, as well as patients with other cancers.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2023)
Article
Medicine, Research & Experimental
Sarah C. Cowles, Allison Sheen, Luciano Santollani, Emi A. Lutz, Brianna M. Lax, Joseph R. Palmeri, Gordon J. Freeman, K. Dane Wittrup
Summary: Monoclonal antibodies targeting PD-1 show varied efficacy depending on their affinity, and a threshold affinity is required for maximum efficacy in the treatment of MC38 adenocarcinoma.
Article
Multidisciplinary Sciences
Vijayakumar Velu, Kehmia Titanji, Hasan Ahmed, Ravi Dyavar Shetty, Lakshmi S. Chennareddi, Gordon J. Freeman, Rafi Ahmed, Rama Rao Amara
Summary: The study demonstrated that PD-1 blockade following ART interruption significantly enhances the function of anti-viral CD8 T cells and improves viral control. It suggests the potential synergistic effects of PD-1 blockade with other immunotherapies inducing functional CD8 T-cell responses.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Automation & Control Systems
Young Gyun Kim, Gyeongbin Mun, Myungjoon Kim, Byoungjun Jeon, Jong Hyeon Lee, Dan Yoon, Byeong Soo Kim, Seong-Ho Kong, Chang Wook Jeong, Kyu Eun Lee, Minwoo Cho, Sungwan Kim
Summary: This study demonstrates that using virtual reality goggles (VR goggles) instead of stereo viewers can improve convenience and satisfaction for surgeons without compromising surgical performance. By adopting VR goggles, the volume of the surgical vision system can be significantly reduced, making VR goggles a promising candidate for further research on enhancing the RAS platform.
INTERNATIONAL JOURNAL OF CONTROL AUTOMATION AND SYSTEMS
(2022)
Article
Endocrinology & Metabolism
Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee, You Jin Lee, Sue K. Park, Do Joon Park, Ji-hoon Kim, Young Joo Park
Summary: This multicenter prospective cohort study conducted in Korea suggests that the risk of progression during active surveillance (AS) for low-risk papillary thyroid microcarcinoma (PTMC) is low in the Korean population, but slightly higher than in other populations. Younger age, male sex, and larger tumor size were identified as independent significant factors for disease progression during AS.
Article
Endocrinology & Metabolism
Hyejo Ryu, Hong-Gyun Wu, Kyu Eun Lee, Eun-Jae Chung, Soon-Hyun Ahn, Young Joo Park, Hoon Sung Choi
Summary: In this retrospective study, the efficacy and safety of postoperative radiotherapy (PORT) for differentiated thyroid cancer (DTC) with high risk features were evaluated. Results showed that PORT can reduce locoregional recurrence in DTC patients without severe toxicity. Further studies are needed to identify the patients who can benefit from PORT.
CLINICAL ENDOCRINOLOGY
(2023)
Article
Otorhinolaryngology
Ja Kyung Lee, Jee-Hye Choi, Woochul Kim, Hyeong Won Yu, Su-jin Kim, Young Jun Chai, June Young Choi, Jae Hyun Kim, Kyu Eun Lee
Summary: A case of a 5-year-old patient undergoing BABA robotic thyroidectomy for Graves' disease is presented, showing the similarities and differences compared to adult patients. The surgery was performed similarly to adults without the need for additional working space. The patient had a smooth recovery with minimal scarring.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Letter
Endocrinology & Metabolism
Jee-Hye Choi, Ja Kyung Lee, Woochul Kim, Hyeong Won Yu, Su-jin Kim, Young Jun Chai, June Young Choi, Kyu Eun Lee
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Surgery
JungHak Kwak, Hyeong Won Yu, Jong-Hyuk Ahn, Su-Jin Kim, Young Jun Chai, June Young Choi, Kyu Eun Lee
Summary: This study examined the trends in surgical outcomes for patients who underwent bilateral axillo-breast approach robotic thyroidectomy (BABA RT) over the past 14 years. The study found that with advancements in robotic surgical systems and improvements in the BABA RT technique, surgical indications have expanded to include more advanced thyroid diseases, and surgical outcomes have improved over the last 14 years.
WORLD JOURNAL OF SURGERY
(2023)
Article
Oncology
Liya Ding, Qiwei Wang, Antons Martincuks, Michael J. Kearns, Tao Jiang, Ziying Lin, Xin Cheng, Changli Qian, Shaozhen Xie, Hye-Jung Kim, Inga-Maria Launonen, Anniina Faerkkilae, Thomas M. Roberts, Gordon J. Freeman, Joyce F. Liu, Panagiotis A. Konstantinopoulos, Ursula Matulonis, Hua Yu, Jean J. Zhao
Summary: This study reveals an adaptive immunosuppression mechanism that leads to resistance to PARP inhibition in BRCA1-mutant ovarian tumors. This resistance is mediated by an increased population of protumor tumor-associated macrophages (TAMs) and activation of the STAT3 signaling pathway. The use of STING agonists can reshape the immunosuppressive tumor microenvironment and overcome PARPi resistance in ovarian cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
Heng-Jia Liu, Heng Du, Damir Khabibullin, Mahsa Zarei, Kevin Wei, Gordon J. Freeman, David J. Kwiatkowski, Elizabeth P. Henske
Summary: This study reveals that B7-H3 expression is correlated with immunosuppressive phenotypes and worse clinical outcomes in human tumors with high mTORC1 activity. The authors show that mTORC1 upregulates B7-H3 expression by phosphorylating the transcription factor YY2. Inhibiting B7-H3 enhances T-cell activity and induces tumor cell expression of MHC-II, suppressing tumor growth with mTORC1 hyperactivity.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Jing Liu, Xia Bu, Chen Chu, Xiaoming Dai, John M. Asara, Piotr Sicinski, Gordon J. Freeman, Wenyi Wei
Summary: The protein arginine methyltransferase PRMT1 suppresses the anti-tumor immune response by methylating cGAS and preventing its dimerization. Inhibition of PRMT1 activates the cGAS/STING-dependent DNA sensing signaling and increases the expression of interferon response genes, tumor-infiltrating lymphocytes, and tumoral PD-L1. Combination therapy of PRMT1 inhibitor with anti-PD-1 antibody enhances the anti-tumor therapeutic efficacy.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, Research & Experimental
Satomi Ando, Charles M. Perkins, Yamato Sajiki, Chase Chastain, Rajesh M. Valanparambil, Andreas Wieland, William H. Hudson, Masao Hashimoto, Suresh S. Ramalingam, Gordon J. Freeman, Rafi Ahmed, Koichi Araki
Summary: T cell exhaustion is associated with dysfunction and expression of PD-1. mTOR inhibition during the expansion phase enhances T cell response, while inhibition after exhaustion progresses causes immunosuppression with decreased TIM3(+) cells and increased viral load. mTOR signaling is essential for differentiation of stem-like T cells into TIM3(+) cells.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Medical Informatics
Inhwa Yoo, Hyoun-Joong Kong, HyunJin Joo, Yeonjin Choi, Suk Wha Kim, Kyu Eun Lee, Jeeyoung Hong
Summary: This study aimed to compare the user experience differences of elderly women participating in remote sports exercise programs using tablet and augmented reality (AR) glasses. The results showed no significant differences in attractiveness, stimulation, and novelty between the two groups, but there were significant differences in efficiency, perspicuity, and dependability. Therefore, when developing AR glasses-based exercise programs for the elderly, the efficiency, clarity, and stability of the program should be considered to meet participants' needs.
HEALTHCARE INFORMATICS RESEARCH
(2023)
Article
Endocrinology & Metabolism
Ja Kyung Lee, Jee-Hye Choi, Woochul Kim, JungHak Kwak, Hyeong Won Yu, Su-jin Kim, Young Jun Chai, June Young Choi, Kyu Eun Lee
Summary: This study retrospectively evaluated the clinical characteristics and surgical outcomes of 26 pediatric patients aged 5-18 years who underwent BABA robotic thyroidectomy. The operation time and surgical completeness were similar to robotic thyroidectomy in adults, and most complications were minor and transient. Therefore, robotic thyroidectomy can be considered as a surgical option regardless of patient age or diagnosis.